Oral Anticoagulation in 2017

Thomas Vanassche, Frans Van De Werf Frans


In this paper we describe the properties and clinical use of new anticoagulants:dabigatran (a direct thrombin inhibitor) and direct anti-Xa agents (rivaroxaban, apixaban,edoxaban ). Major studies that have been performed with these agents in comparisonwith warfarin are reported. Recommendations for use in clinical practice are provided.Information on the disappearance of the anticoagulant effect after stopping drug intakeand on the administration of agents that neutralize the effect of the new anticoagulantis provided.

Keywords :
warfarin, dabigatran, anti-Xa agents, idarucizumab

Address Correspondence to author:
Frans Van, MD, PhD, FESC, FACC, FAHA Department of Cardiovascular Sciences University Hospital Leuven Herestraat-49, B-3000 Leuven, Belgium email: frans.vandewerf@uzleuven.be

Received: November 10, 2018
Revision received: December 28, 2018
Accepted after revision: January 10, 2018
BKK Med J 2018;14(2): 81-94.

DOI: 10.31524/bkkmedj.2018.09.015

Full Text: